A political firestorm has been brewing in Formula 1 in recent weeks and months over whether engine manufacturers have found a loophole in the new 2026 technical regulations. Mercedes and Red Bull may ...

Abstract: The uneven allocation of single-phase residential systems and rooftop photovoltaic systems in low-voltage distribution networks leads to three-phase active power unbalance, adversely ...

In power distribution systems, three-phase transformer configuration directly impacts system reliability and load management. Understanding the trade-offs between Delta and Wye connections enables ...

Three years ago, the data center industry debated whether liquid cooling would ever be necessary. Two years ago, most operators believed single-phase water would be the solution. Today, leading ...

As the year comes to an end, we must be thankful for the therapies that are in late clinical stages. Most importantly, patients are set to benefit immensely. But nearly every trial candidate has ...

IgA nephropathy, the most common primary glomerulopathy worldwide, is a kidney disorder of B-cell origin characterized by mesangial accumulation of IgA-containing immune complexes. In at least 50% of ...

CINCINNATI--(BUSINESS WIRE)--Edge Energy, a leader in innovative energy solutions, today announced a collaborative next-generation solution with Lincoln Electric that is designed to bring, fast ...

Telitacicept, a new dual inhibitor of the cytokines B-lymphocyte stimulator (BLyS) and APRIL (a proliferation-inducing ligand), showed efficacy in adults with active systemic lupus erythematosus (SLE) ...

MoonLake Immunotherapeutics’ stock has taken a pummeling after the biotech blamed an unexpectedly high placebo response rate for its much-hyped inflammatory disease prospect missing the key goal of ...

Bausch Health has struck a deal to buy Durect for $63 million upfront, landing a phase 3-ready liver disease candidate that the companies believe has blockbuster potential. Durect reported top-line ...

AXPAXLI, a bioresorbable hydrogel with axitinib, is being tested for wet AMD and other retinal diseases in the SOL-R trial. The SOL-R trial involves 555 patients across multiple countries, comparing ...